Should I Buy AIM? AIM 2026 Analysis

Should You Buy AIM ImmunoTech Inc (AIM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.150

1 Day change

-5.74%

52 Week Range

20.330

Analysis Updated At

2026/01/28

AIM ImmunoTech (AIM) is not a good buy right now for a beginner, long-term investor with $50k–$100k who wants to act immediately. The stock is in a bearish technical structure, fundamentals show declining revenue with sizable losses, and the latest key event (a rights offering) is near-term dilution risk. Unless you already own it for speculative biotech optionality, this setup is an avoid/sell rather than a long-term buy today.

Technical Analysis

Price/levels: Pre-market at 1.18, below the pivot (1.256) and just above near-term support S1 (1.157). This suggests weak momentum and a risk of testing support; resistance overhead starts at 1.355 (R1). Trend: Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downtrend across long-, mid-, and short-term timeframes. Momentum: MACD histogram is slightly positive (0.00392) but positively contracting—often read as fading upside momentum rather than a fresh breakout. RSI(6) ~43 is neutral-to-soft, not signaling an oversold bounce. Pattern-based outlook: Similar-pattern stats imply modest upside probabilities (+0.79% next day, +1.89% next week, +1.8% next month), but this is not strong enough to offset the broader bearish structure. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

- Rights offering is expected to raise ~$12M, which could extend runway for clinical trial expenses and support operations.
- If trial progress updates follow funding, the stock could see event-driven spikes typical of small-cap biotech.

Neutral/Negative Catalysts

- Proposed rights offering is a dilution overhang and often pressures the share price in the near term.
- No supportive hedge fund/insider trend signal (both neutral), reducing confidence that informed buyers are stepping in.
- Micro-cap biotech profile with weak financials increases financing and execution risk.

Financial Performance

Latest quarter: 2025/Q3. Revenue fell to ~$26K (-25.71% YoY), while net income remained deeply negative at about -$3.284M (down -11.24% YoY). EPS was -1.57 (down -75.51% YoY). Gross margin was sharply negative (-161.54), indicating the company is far from operating leverage and remains dependent on external funding—consistent with the new capital raise.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided. Wall Street pro/con view cannot be reliably summarized from the dataset; based on the available fundamentals and dilution event, the near-term professional-style view would skew cautious/negative until financing terms and clinical milestones improve. Politician/congress activity: No recent congress trading data available.

1 Analyst Rating

Wall Street analysts forecast AIM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AIM is 22 USD with a low forecast of 22 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.220

Low

Averages

High